Anyhow, we are very underexposed to healthcare since we like 20%+ type of growth and only so many companies can provide it. We've had a few ventures with Myriad Genetics (MYGN) the past 2.5 years, some successful - some not. The stock has just broken out from below some resistance areas so I am going to give it another shot, with a 2% allocation around $25.60. We last closed out a position in Myriad in early November about a dollar lower than this level - so we have not missed much.
[click to enlarge]
The stock has bow broken over the 50 day moving average after going sideways for much of the past 2 months, we'll use the 20 and 50 days as new support levels / stop out levels. If it can continue to move, it should have relatively clear sailing until running into the 200 day moving average up near $28 (and falling)
With earnings of $1.45 (est.) for year end Jun 2010, the forward PE is under 20, for a 20% type of grower. The stock has simply been in the doghouse for much of 2009, unlike its superstar status in 2008. Hopefully ti can catch some mojo in 2010.
[Jan 20, 2009: Myriad Genetics - Another Diagnostic Heavy Hitter]
Long Myriad Genetics in fund; no personal position